On the other hand, Touré et al. found they most frequently occurred in patients with SSc among all aPL-determined aCL (in 17.5% of patients) and anti-β2GPI antibodies (in 37.5% of patients) [15]. This evidence concerns the gene ACLY and systemic sclerosis.